The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC)

NCT06861543 | Recruiting Phase 1

• 1 other identifier: TMT101-01
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

This is a first-in-human, single-arm, open-label, dose escalation prospective phase I clinical study to evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Alone in patients with Unresectable, Metastatic or Advanced pancreatic cancer or Non-small Cell Lung Cancer(NSCLC) after Standard Treatment Failure. The primary objective is to evaluate the safety and tolerability of TMT101 Injection as monotherapy in patients with advanced pancreatic cancer and NSCLC, and to determine the recommended therapeutic dose (RD) of TMT101 Injection as monotherapy

Conditions

Non-small Cell Lung Cancer

Keywords

TMT101 Injection; mRNA; advanced pancreatic cancer or NSCLC

Outcome Measures

Primary Outcomes (6)

• dose-limiting toxicities (DLTs)

  Occurrence of dose-limiting toxicities (DLTs) within 21 days since the first dose

  within 21 days since the first dose

• treatment-emergent adverse events (TEAEs)

  occurrence of treatment-emergent adverse events (TEAEs) and grade according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0

  up to 2 years

• treatment related adverse event (TRAE)

  Occurrence and grade of treatment related adverse event (TRAE) according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0

  up to 2 years

• immune-related Adverse Event(irAE）

  Occurrence and grade of immune-related Adverse Event(irAE）according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0

  up to 2 years

• Serious Adverse Event(SAE）

  Occurrence and grade of Serious Adverse Event(SAE）according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0

  up to 2 years

• Recommended Dose（RD）

  During the dose escalation phase, the MTD and/or available safety, biomarker, and efficacy data will be evaluated thoroughly to determine the RD of TMT101 Injection alone . Three dose levels are planned to be explored: 0.1 mg, 0.2 mg, and 0.4 mg. Once the initial dose is 0.1 mg with a dose reduction for safety reasons, the level of dose reduction will be discussed jointly between the investigator and the sponsor. If the highest dose level of 0.4 mg is not confirmed as a possible recommended therapeutic dose (RD), it may be escalated to a higher dose to determine the possible RD under the condition that investigator and the sponsor to decide together.

  the whole escalation phase within 21 days since the first dose

Secondary Outcomes (7)

• Objective response rate (ORR)

  up to 2 years

• Disease control rate (DCR)

  up to 2 years

• Progression-free survival (PFS)

  up to 2 years

• Overall survival (OS)

  up to 2 years

• Peak time (Tmax) of cationic lipids

  up to 9 weeks

Study Arms (1)

TMT101 Injection monotherapy

EXPERIMENTAL

Three dose levels are planned to be explored: 0.1 mg, 0.2 mg, and 0.4 mg. The initial dose is 0.1 mg with a dose reduction for safety reasons, the level of dose reduction will be discussed jointly between the investigator and the sponsor. TMT101 will be injected intramuscularly, Once a week,a total of 9 times

Biological: TMT101 Injection

Interventions

TMT101 Injection BIOLOGICAL

Three dose levels are planned to be explored: 0.1 mg, 0.2 mg, and 0.4 mg. The initial dose is 0.1 mg with a dose reduction for safety reasons, the level of dose reduction will be discussed jointly between the investigator and the sponsor. TMT101 will be injected intramuscularly, Once a week,a total of 9 times

TMT101 Injection monotherapy

Eligibility Criteria

• Age: 18 Years+
• Gender Eligibility Details: regardless of gender
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Agrees to follow the trial protocol and visit schedule, has signed informed consent;
• Subjects must be ≥18 years of age at time of informed consent,regardless of gender;
• Patients with advanced/unresectable or metastatic pancreatic cancer or non-small cell lung cancer that requires histologically and/or cytologically confirmed according to the American Joint Committee on Cancer 8th edition; pancreatic cancer:Previous failure or intolerance of two or more lines of chemotherapy; NSCLC:Previous failure or intolerance of platinum-containing chemotherapy and anti-PD-1/PD-L1 monoclonal antibodies, regardless of combination therapy or sequential therapy, if the previous test for EGFR-sensitive mutations or ALK fusion genes is positive, treatment with a third-generation TKI must be failed or intolerant;
• At least one evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;
• ECOG≤1;
• Estimated life expectancy≥12 weeks;
• Adequate organ function, meet the following laboratory standards:
• ANC≥1.5×109/L;PLT≥90×109/L;
• Hb≥90 g/L;
• TBIL≤1.5×ULN, Patients with Gilbert's syndrome ; without liver metastases, AST and ALT ≤ 2.5×ULN;liver metastases, AST and ALT ≤5×ULN ;
• Ccr≥50 mL/min;
• INR≤1.5×ULN, APTT≤1.5×ULN;
• Males of childbearing potential and females of childbearing potential who are willing to use effective contraception since signing the informed consent until 6 months after the last dose of the trial drug. Females of childbearing potential must have a negative pregnancy test result within 7 days prior to the first dose.

You may not qualify if:

• Allergic to TMT101 Injection or any of the components in the prescription;
• Uncontrolled illness including, but not limited to, active infection requiring systemic therapy, uncontrolled hypertensionuncontrolled hyperglycemia, decompensated congestive heart failure , unstable angina, arrhythmias that require clinical intervention; ascites or uncontrolled pleural effusion (CTCAE 5.0≥grade 2), thrombosis (such as pulmonary embolism, cerebral infarction, myocardial infarction) or history of stroke, active autoimmune disease, psychiatric disease, active peptic ulcer disease, active bleeding disorder, which would limit compliance with study requirements or impair the patient's ability to sign informed consent in writing;
• Patients who used immunosuppressive drugs within 3 weeks prior to the first dose, or patients who have achieved immunosuppressive intent (dose \> 10 mg/day prednisone or other equivalent hormones and the duration of use is at least 7 days ) on systemic hormonal therapy or absorbable topical hormonal therapy, with the exception of physiologic doses of intranasal and inhaled corticosteroids;
• Within 4 weeks prior to the first administration, received major surgery, radiotherapy (except palliative radiotherapy for bone metastasis), or treatment for surgical wounds that were not healed, ulcerated, or fractured; within 4 weeks prior to the first administration or within 5 half-lives (whichever is shorter) received anti-tumor treatments such as chemotherapy, biological therapy, endocrine therapy, targeted therapy, or immunotherapy.
• Patients with prior or concurrent occurrence of other malignancies, with the following exceptions: a) Carcinoma in situ of the cervix or breast, curatively treated with no signs of recurrence for at least 3 years prior to the study; b) The primary malignancy was completely resected and in complete remission for ≥ 5 years;
• History of interstitial lung disease or current interstitial lung disease or suspected of such disease by imaging during screening. and pneumonitis that previously required systemic corticosteroid treatment;
• Treponema pallidum antibody or human immunodeficiency virus (HIV) antibody positive, positive for hepatitis C virus antibody and hepatitis C virus (HCV) RNA, or active hepatitis B (positive for hepatitis B surface antigen and HBV DNA ≥ upper limit of normal);
• Received live vaccines within 4 weeks before the first dose or planned to receive live vaccines during the study period and within 4 weeks after the last dose, including but not limited to: measles, mumps, rubella, chickenpox, yellow fever, rabies, BCG and typhoid vaccines;
• History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation;
• Patients who have had a previous ≥grade 3 immune-related adverse event or immunotherapy-related serious adverse event (SAE) leading to permanent discontinuation;
• Pregnant or lactating females;
• In the opinion of the investigator, the subject has other conditions that may affect compliance or are not suitable for participation in this study;
• Patient has active central nervous system metastases (with or without treatment), including symptomatic brain metastases or meningeal metastases or spinal cord compression, but asymptomatic brain metastases except;
• Within 4 weeks prior to the first dose, all toxicities from prior antineoplastic therapy have not recovered to grade 1 or less, with the following exceptions: a. alopecia, b. long-term toxicity caused by radiotherapy, c. other toxicities that cannot be recovered in the judgment of the investigator but have no effect on the subject's administration
• Major surgery within 4 weeks prior to the first dose;

Sponsors & Collaborators

• Peking Union Medical College Hospital: lead

Study Sites (1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China

RECRUITING

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Wenming Wu, PhD

  Peking Union Medical College Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Wenming Wu, PhD

CONTACT

010-69156874; pumchkyc@126.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director, Chief Physician of Basic Surgery, Principal Investigator, Clinical Professor

Model Details: TMT101 Injection alone

Study Record Dates

• First Submitted: February 8, 2025
• First Posted: March 6, 2025
• Study Start: March 1, 2025
• Primary Completion: December 1, 2025
• Study Completion (Estimated): July 1, 2026
• Last Updated: August 11, 2025

Record last verified: 2025-02

Locations

CN (1)